PT - JOURNAL ARTICLE AU - Sajib, Mohammad Saiful Islam AU - Oravcova, Katarina AU - Brunker, Kirstyn AU - Everest, Paul AU - Fuentes, Manuel AU - Wilson, Catherine AU - Murphy, Michael E. AU - Forde, Taya TI - Rapid and modular workflows for same-day sequencing-based detection of bloodstream infections and antimicrobial resistance determinants AID - 10.1101/2024.10.09.24315014 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.09.24315014 4099 - http://medrxiv.org/content/early/2024/10/09/2024.10.09.24315014.short 4100 - http://medrxiv.org/content/early/2024/10/09/2024.10.09.24315014.full AB - Background Bloodstream infections (BSI) are a major global health concern, and existing diagnostic methods are too slow to guide targeted antibiotic therapy for critically ill patients, risking poor clinical outcomes. Rapid metagenomic-sequencing (mNGS) can facilitate swift pathogen and antimicrobial resistance (AMR) detection, but identification is challenged by significant host versus bacterial DNA in blood. To accelerate microbiological diagnosis, we developed M-15, a rapid and modular mNGS-based host DNA depletion workflow, validated with suspected BSI blood-culture samples and rapid culture-enriched spiked blood.Methods To assess chemical host DNA depletion (CHDD) efficiency, M-15 was benchmarked with five commercial/published protocols. Later, M-15 was combined with rapid mNGS with/without adaptive sampling (AS) and tested on clinical blood-culture samples (n=33) from suspected BSI cases identified on BACT/ALERT VIRTUO (30 flagged positive, three remained negative). To determine whether it is possible to utilise M-15 mNGS prior to blood-culture flagging positive, a rapid enrichment method was tested starting with 1-10 colony forming units of the top 15 bacterial species causing BSI spiked into BACTEC medium enriched with 10 mL sheep blood.Results All six chemical depletion protocols reduced host DNA by 2.5×100 to 4.1×106-fold, with the in-house M-15 protocol performing best, while adaptive sampling depleted host >5-fold. With BACT/ALERT specimens, M-15 mNGS accurately identified 3/3 negative, 28/28 mono-bacterial, and 2/4 multi-bacterial species. With rapid culture-enrichment and M-15 mNGS, <18% DNA was classified as host and all bacterial species tested (n=10) were correctly identified. M-15 mNGS accurately predicted phenotypic AMR/susceptibility for 90.3% (232/257) of drug/bacteria combinations from BACT/ALERT positive samples.Conclusions This study demonstrates that M-15 mNGS can facilitate species and AMR gene detection within 5-7 hours of BACT/ALERT positivity. Including 8-hour culture enrichment, microbiological and AMR confirmation is possible within 13-15 hours of sample collection. Thus, the M-15 mNGS workflow has the potential to improve patient outcomes in BSI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Royal Society Research Grant (RGS\R1\211163) and University of Glasgows Lord Kelvin Adam Smith (LKAS) Ph.D. studentship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the University of Glasgow College of Medical, Veterinary & Life Sciences Ethics Committee (Project No: 200210015) and UK National Health Services (NHS) Greater Glasgow and Clyde (R&I reference: GN19ID331). No personal information from the patients and healthy volunteers was collected and used in this study. Human DNA reads obtained from mNGS were excluded or not utilised for any bioinformatics analyses beyond quantifying the number of hosts reads generated.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAMRAntimicrobial resistanceASAdaptive samplingASTAntimicrobial susceptibility testingATCCAmerican Type Culture CollectionBSIBloodstream infectionBPMBases per millionCFUColony-forming unitsCHDDChemical host DNA depletion dsDNADouble-stranded DNAEUCASTEuropean Committee on Antimicrobial Susceptibility TestingFDAFood and Drug Administration (USA)GC%Guanine-cytosine content percentagemNGSMetagenomic next-generation sequencingMbpMegabase pairsMDAMultiple displacement amplificationNHSNational Health Service (UK)ONTOxford Nanopore TechnologiesPBSPhosphate-buffered salineqPCRQuantitative polymerase chain reactionRBCRed blood cellsWGAWhole-genome amplificationWGSWhole-genome sequencing